Lixte's stock price drops by 16%, plans to invest 25% of funds in Bitcoin Lixte Biotechnology (LIXT) closed at $4.06 on Wednesday, down 16%. Previously, the company announced plans to allocate up to 25% of its reserve funds to Bitcoin. Market analysis suggests that investors are increasingly favoring Ethereum reserve companies in recent times, as ETH has performed better than Bitcoin. Bitwise analysts predict that 2025 may be the year of Ethereum's reserve strategy.